Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study

Table 5 Unadjusted and adjusted models of adherence-related predictors of SVR among the study population

	SVR (%)	Unadjusted OR	95% CI	P	Adjusted OR	95% CI	P
95% ribavirin adherence*
No	17 (63)	1.00	-	-	-	-	-
Yes	44 (73)	1.62	0.61–4.26	0.330	-	-	-
100% PEG-IFN adherence*
No	58 (67)	1.00	-	-	-	-	-
Yes	3 (50)	2.00	0.38–10.53	0.413	-	-	-
Completed therapy
No	2 (9)	1.00	-	-	1.00	-	-
Yes	59 (83)	34.41	6.90–171.55	0.000	23.86	2.94–193.84	0.003

The adjusted model is adjusted for all factors associated with SVR from the primary analysis [11]
*On-treatment adherence

ISSN: 1471-2334